RxDoctor Payments DataLook up a doctor →

Velta Willis, NP

Nurse Practitioner · Brooklyn, NYNPI 1831207935

Payments from drug & device makers

$19,060in general payments, 2019–2025

Across 842 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Seagen Inc.$1K
  • Lilly USA, LLC$1K
  • Merck$1K
  • Incyte Corporation$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $12K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer68$1,464
Seagen Inc.42$1,362
Lilly USA, LLC58$1,280
Merck42$1,184
Incyte Corporation40$1,169
E.r. Squibb & Sons, L.L.C.96$1,089
Eisai Inc.53$925
Astellas Pharma US Inc27$907
Johnson & Johnson(2 entities)32$903
Bristol Myers Squibb37$797
AstraZeneca(2 entities)34$797
Novartis47$745
Daiichi Sankyo Inc.39$731
Amgen15$498
Gilead16$427
Taiho Oncology, Inc.22$378
Puma Biotechnology, Inc.17$369
Takeda Pharmaceuticals U.S.A., Inc.7$316
Genmab U.S., Inc.15$285
Boehringer Ingelheim10$224
Stemline Therapeutics Inc.10$221
Array Biopharma Inc9$196
Exelixis Inc.3$182
Sanofi8$181
Sanofi-aventis U.S. LLC2$150
AbbVie3$148
Beigene USA, Inc.1$125
Myovant Sciences Inc.5$120
Mylan Institutional Inc.6$116
Accord Healthcare, Inc.3$116
Agios Pharmaceuticals, Inc.4$104
Bayer5$101
Novocure Inc.5$100
Tactile Systems Technology Inc3$94
Mirati Therapeutics, Inc.5$90
Springworks Therapeutics, Inc.4$90
GSK4$89
Deciphera Pharmaceuticals Inc.4$88
Apellis Pharmaceuticals, Inc.3$77
Coherus Oncology, Inc.4$75
Rigel Pharmaceuticals, Inc.3$74
Blueprint Medicines Corporation3$65
Sumitomo Pharma America, Inc.3$58
Octapharma USA, Inc.2$55
Tersera Therapeutics LLC3$53
Acrotech Biopharma Inc.2$53
Karyopharm Therapeutics Inc.2$50
Dova Pharmaceuticals2$42
Syndax Pharmaceuticals, Inc.2$35
AMAG Pharmaceuticals, Inc.2$32
Dendreon Pharmaceuticals LLC1$32
Pharmacosmos Therapeutics Inc.1$31
Pharmacyclics LLC, An Abbvie Company1$27
Global Blood Therapeutics, Inc.1$25
Adaptive Biotechnologies Corporation1$25
G1 Therapeutics, Inc.1$20
Regeneron Healthcare Solutions, Inc.1$19
Recordati_rare_diseases_inc.1$19
Servier Pharmaceuticals LLC1$19
Pharmaessentia USA Corporation1$17

How this compares

$19,060 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York →

Medicare billing

Part B allowed, 2024
$903
Medicare patients
11
Services billed
12

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Brooklyn

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →